HER2 Archives - Medical Conferences

Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma

Presented By

Prof. Aziz Zaanan, Université Paris Cité, France

Trial

Phase 3, GASTROFOX

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:30

Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:31

Promising phase 2 results for HER-Vaxx in gastric cancer

Presented By

Dr Tanuj Chawla, Tata Medical Center, India

Trial

Phase 2, HERIZON

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:00

Practice-changing results of T-DXd in HER2-low breast cancer

Presented By

Prof. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DESTINY-Breast04

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:04

Trastuzumab deruxtecan triples PFS

Presented By

Dr Javier Cortés, International Breast Cancer Center Barcelona, Spain

Trial

Phase 3, DESTINY-Breast03

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:51

Novel conjugate meets primary endpoint

Presented By

Dr Cristina Saura, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, TULIP

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:50

Meta-analysis shows 6-months adjuvant trastuzumab is optimal

Presented By

Prof. Helena Earl, Addenbrooke's Hospital, UK

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:50

Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy

Presented By

Prof. Valentina Guarneri, University of Padua, Italy

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:48

HIPEC in gastric cancer with peritoneal metastases

Presented By

Prof. Beate Rau, Charité University Hospital Berlin, Germany

Trial

Phase 3, GASTRIPEC I

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

Presented By

Dr Alexander Stein, University Cancer Center Hamburg, Germany

Trial

Phase 2, INTEGA

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:39

Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Presented By

Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, DESTINY-Lung01

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:36

Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer

Presented By

Dr Eugene Ahn, Cancer Treatment Centers of America, IL, USA

Trial

Phase 2, TAPUR

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:45

Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:10

Trastuzumab-deruxtecan showed clinical activity in patients with brain metastases

Presented By

Prof. Guy Jerusalem , CHU Liège, Belgium

Trial

Phase 2, DESTINY-Breast01

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 19:54

Adding neoadjuvant anastrozole to trastuzumab deruxtecan in HER2-low breast cancer

Presented By

Dr Sarah Hurvitz , UCLA Jonsson Comprehensive Cancer Center

Trial

Phase 2, TALENT

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:34

Preventing interstitial lung disease in patients on trastuzumab deruxtecan

Presented By

Dr Charles Powell, Mount Sinai-National Jewish Health Respiratory Institute

Trial

Phase 2, DESTINY-Breast01

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:10

T-DXd response on brain metastases in HER2+ breast cancer patients

Presented By

Prof. Guy Jerusalem, Liège University, Belgium

Trial

Phase 2, DESTINY-Breast01

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:48

T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Presented By

Dr Fabrice André, Institut Gustave Roussy, Paris, France

Trial

Phase 2, DESTINY-Breast07

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 10:55

HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

Expert

Prof. Salvatore Siena, University of Milan Niguarda Cancer Center, Italy

Trial

Phase 3, DESTINY-CRC01

Conference

ASCO 2020

17 September 2020 15:00

T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported

Presented By

Prof. N. Harbeck, University of Munich, Germany

Trial

Phase 3, KAITLIN

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 09:40

PHOEBE, a phase 3 trial comparing pyrotinib and lapatinib in HER2-positive metastatic breast cancer

Presented By

Dr Binghe Xu, Peking Union Medical College, China

Trial

Phase 3, PHOEBE

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 09:10

Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer

Presented By

Dr Javier Cortés, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 2, PHERGAIN

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 08:50

No higher pathologic complete response with atezolizumab added to chemotherapy

Trial

IMpassion130

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 23:54

S-1 shows promising results in combination with endocrine therapy

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 23:40

Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer

Trial

APHINITY

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 23:13

High rates of ROR-low disease with chemotherapy-free regimen in HR+/HER2- patients

Trial

Phase 2, CORALLEEN

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 23:05

Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement

Trial

KEYNOTE-173, Phase 1b ; I-SPY 2, Phase 2 ; KEYNOTE-522, Phase 3

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 22:56

HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients

Trial

Phase 2, DESTINY-Breast01

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 22:54

Partial breast irradiation could be as effective as whole breast irradiation

Trial

Phase 3, APBI IMRT

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 22:48

Subcutaneous pertuzumab + trastuzumab non-inferior to the IV combination

Trial

Phase 3, FeDeriCa

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 21:44

Palbociclib not statistically superior to capecitabine in PFS

Trial

Phase 3, PEARL

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 13:21

Clinical benefit over trastuzumab for margetuximab in HER2 breast cancer

Trial

Phase 3, SOPHIA

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 12:45

Residual cancer burden is a predictor for all-type breast cancer patients

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 12:11

Tamoxifen monotherapy may mean undertreatment for some luminal breast cancer patients

Trial

MINDACT, TAILORx

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 10:01

Discordance of biomarkers in multifocal and lymph node positive breast cancer

Presented By

Dr Marie Sundquist, Kalmar County Hospital, Sweden

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 23:51

Extrapolating data from clinical trials as we treat patients in real life

Presented By

Prof. Sharon Giordano, MD Anderson, Houston, USA

Trial

APHINITY, KATHERINE, ExteNET

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 23:44

Adjuvant Her2-targeted therapy

Trial

APHINITY

Conference

BCC 2019

Type

Peer-reviewed article

21 May 2019 13:35